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Hypoplastic left heart syndrome – unresolved issues
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Hypoplastic left heart syndrome (HLHS) is one of the most challenging congenital heart
defects. At present, it is expected that – at best – 70% of newborns with HLHS will
reach adulthood. This review addresses the problems of right ventricular (RV) failure and
insufficient growth of pulmonary vasculature in these patients. In order to further improve
long-term prognosis translational research to control RV function, growth of pulmonary
arteries and progress in chronic circulatory support are clearly needed to provide a further
improvement for adults with HLHS.
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Hypoplastic left heart syndrome (HLHS) is one of the most
challenging congenital heart defects. A recent meta-analysis has
shown that regarding the time period from 1980 to 2010, the
mean survival after the stage I Norwood procedures was about
80% (1). Achievements in perioperative management and post-
operative intensive care have made these advances possible. At
present, the 30 days survival of patients with HLHS undergo-
ing Norwood repair is as high as 89.8% [UK-data published
by the National Institute for Cardiovascular Outcomes Research
(NICOR)] (2). Cumulative data presented by the European Associ-
ation for Cardio-Thoracic Surgery (EACTS) report an In-Hospital
Mortality of 37.78% in 582 patients undergoing stage I Norwood
palliation (3). Clearly, a dedicated team is of utmost importance
for the care of HLHS patients, the NICOR data show that caseload
alone is not the only parameter to lead to low mortality.
Some authorities have optimistic views on life expectation for
patients with HLHS in the present era: after additional stage II and
stage III (total cavopulmonary connection) it is expected that 70%
of newborns with HLHS will reach adulthood (4).
Reports on the fate of young adults with HLHS are scarce (5)
and data summarizing the fate of these patients as adults (i.e.,
>18 years of age) are lacking.
Data published by Hansen and coworker in 2012 reported 186
surviving patients after the Norwood procedure with the longest
follow-up of 15.1 years (6). It is therefore far too early to speculate
on potential survival in the third or fourth decade of life in HLHS
patients.
The fact that the systemic ventricle has right ventricular (RV)
morphology is seen by many authorities as a risk factor, which is
highly associated with long-term mortality and heart failure after
Fontan procedures in patients with HLHS (4). It is quite clear that
even if more patients should reach stage III palliation with even
better management strategies there will be inevitably more patients
presenting with the late complications that are to be expected with
a Fontan physiology.
It is quite obvious that two factors will be of utmost impor-
tant for the success of the three step palliation of HLHS using
the Fontan-concept: (1) the capacity and development of the
pulmonary arterial system and (2) preservation of RV function.
THE PULMONARY CIRCULATION IN PATIENTS WITH HLHS
At stage I, Norwood palliation pulmonary blood flow is estab-
lished via a modified Blalock–Taussig shunt (MBTS) or via a RV
to pulmonary artery shunt (RV-PA shunt – Sano-Shunt). While
the RV-PA shunt is associated with a better immediate postopera-
tive outcome, its effect on growth of pulmonary arteries has been
questioned: the overall size of the pulmonary artery on angiogra-
phy before the stage II procedure was smaller in the RV-PA shunt
group than in the mBT shunt group (7). A series including 549
patients with HLHS (angiography in 389 patients) showed that
mBT shunt patients had larger mid-branch pulmonary arterial
diameters and better Nakata-indices compared to RV-PA-shunt
patients, which in turn demonstrated more shunt or pulmonary
obstruction (8).
The modern hybrid approach using stenting of the arterial
duct and bilateral pulmonary artery banding may also lead to
compromise pulmonary arterial development (9) although this is
controversial at present (10, 11). Many centers perform the hybrid
procedure in HLHS patients with less weight (12).
Theoretically, pulmonary blood flow in the HLHS patient after
stage I Norwood palliation should be high in order to promote
pulmonary arterial growth. However, this would result in an unac-
ceptable burden for the systemic right ventricle. Interstage mor-
tality between stage I and stage II Norwood palliation is reported
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FIGURE 1 | Angiography of superior cavopulmonary anastomosis and
pulmonary arteries in a patient after stage II Norwood palliation. Note
the hypoplasia of pulmonary arteries.
to be between 2 and 16% (4). In this time period, the infants
present with very little cardiopulmonary reserve and need close
monitoring of saturation, weight gain, and enteral intake. There-
fore, the dilemma is quite clear: without proper development of
pulmonary arteries, the patient with HLHS will not be a good
candidate for a Fontan completion (Figure 1). Pulmonary arte-
rial growth in patients with univentricular physiology is greater
in patients with increased pulmonary blood flow prior to Glenn
anastomosis but thereafter the Nakata index and McGoon ratio
decreased significantly (13).
The optimal timing for stage II palliation with superior
cavopulmonary connection is difficult to ascertain, but previous
results argued for an early palliation at a mean age of 4.6 months
(14). The data obtained in this study, however, also showed that the
pulmonary arteries remained too small for the given body surface
area.
The growth of pulmonary arteries in Fontan patients shows a
considerable individual variability (15). The same group showed
that the development of arteriopulmonary malformations in
patients after Glenn anastomosis was inversely related to the
McGoon index, i.e., patients with poor development of pulmonary
arteries are more likely to develop arteriopulmonary malforma-
tions (15). Some groups therefore advocate to leave the RV-PA
shunt intact in patients with HLHS at stage II Norwood palli-
ation in order to promote growth of pulmonary arteries (16).
These authors did not find an increased rate of complications in
the 20 patients with an intact RV-PA-Shunt compared to the 48
patients that had their RV-PA shunt removed at stage II Norwood
palliation (16).
At present, there is no medication with proved efficacy to pro-
mote pulmonary vascular growth in patients with univentricular
physiology. Hypoxia has been shown to be an important factor to
induce angiogenesis in various ischemic models (17). The arterial
(bronchial) blood supply to the lung in HLHS patients at stage I
and II Norwood repair is not fully oxygenated whereas in most
cases there will be no alveolar hypoxia. We know from experimen-
tal studies in ischemic models that stem/progenitor cells with or
without a combination of growth factors will induce neovascular-
ization in various animal models (17). Both changes for growth
factors as well as stem cell recruitment have been described for the
right ventricle in patients with HLHS (18, 19), but there are no
data analyzing their role in pulmonary vascular development in
these patients. A true animal model mimicking HLHS does not
exist, but endocardial fibroelastosis has been reproduced in a rat
model (20).
Pulmonary vascular development and the impact of congenital
heart disease are in the focus of many groups worldwide. Pul-
monary vascular development is a key point for the patient with
HLHS that will determine long-term prognosis. Animal mod-
els such as the neonatal lamb model with increased pulmonary
blood flow have the potential to give insights in the mechanisms
of angiogenesis and potential targets for pharmacotherapy. At
present, it is unlikely to expect new therapeutic strategies in the
near future (21).
THE RIGHT VENTRICLE IN PATIENTS WITH HYPOPLASTIC
LEFT HEART SYNDROME
The right ventricle in HLHS is prone to failure on long-term basis.
In Fontan patients, the presence of a morphological right sys-
temic ventricle is an independent risk factor. A follow-up study
on 1006 survivors of the Fontan procedure in New Zealand and
Australia analyzed survival in 80 patients with HLHS after the
Fontan procedure in the years after 2000. HLHS was the primary
predictor of Fontan failure (hazard ratio, 3.8; P < 0.001; 95% CI,
2.0–7.1) (22). This is consistent with findings in a smaller sub-
population of HLHS patients included in a series of failing Fontan
patients (23) (Figure 2). Tricuspid regurgitation has detrimental
effects on RV function. The mechanism of tricuspid regurgita-
tion in patients with HLHS remains complex and multifactorial:
structural abnormalities of the tricuspid valve (TV) and functional
causes such as RV dysfunction and dilatation of the TV annulus
contribute to this problem. Morphology of the TV preoperatively
such as anterior leaflet prolapse is known to be associated with
worse outcome (24).
The surgical method to direct flow to the lungs at the stage I
palliation influences ventricular function in the future: in a recent
study, Newburger and coworkers (25) analyzed 549 subjects who
underwent the Norwood procedure. By 3 years, the patients after
RV-PA shunt had slightly worse RV ejection fraction (as calcu-
lated on ECHO with the biplane pyramidal method) compared
to patients that were operated using an MBTS. Three years after
stage I palliation, the patients in which the Norwood procedure
was done with RV-PA shunt lost the transplantation-free survival
benefit as compared to the MBTS group (25).
Medical treatment of right heart failure has clear limitations.
ACE – inhibitor therapy has not been convincing in children with
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FIGURE 2 | Right ventricular failure after stage II Norwood palliation is shown. Within 1 year, there is progression from mild tricuspid regurgitation (A) to
severe tricuspid regurgitation with overt heart failure (B).
univentricular heart (26). Recent data show that no single med-
ication is independently associated with better survival or weight
gain during interstage period (27). Again translational research
shows that gene expression and β-adrenergic signaling are altered
in HLHS (28).
Stem cell therapy of heart failure may hold great potential to
treat children with HLHS and heart failure (29). Two clinical tri-
als are underway using autologous umbilical cord blood cells for
HLHS (29), but larger randomized trials are needed to show proof
of efficacy of this therapy in patients with HLHS.
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Heart failure that cannot be improved by medication finally
may lead to heart transplantation in patients with HLHS at any
stage of Norwood palliation (30). However, the operative mortal-
ity for patients with univentricular physiology and failing Fontan
undergoing orthotopic heart transplantation is high. A recent
series reported 23% early mortality. 1-, 5-, and 10-year survival
was 77, 66, and 45%, respectively (31). Some authorities therefore
advocate that it might be better to earlier transplant patients with
HLHS post-Glenn, since these patients were less prone to renal
failure and liver dysfunction (which is present in Fontan failure)
(32). A series comparing 16 transplanted patients with HLHS (11
post-Glenn) with the 154 patients after heart transplantation for
acquired cardiomyopathy (CM) found a 30-day survival of 100%
in the palliated HLHS patients (vs. 98.1% for the CM group), with
1- and 5-year Kaplan–Meier survivals of 100 and 87.5% (P = 0.393
vs. CM; log-rank test) (33).
The use of ventricular assist devices in patients with single-
ventricle physiology has been reported in case reports and small
series (34, 35). In a recent series reporting the use of the
Berlin Heart EXCOR in 281 patients, the VAD was used in 26
patients with univentricular heart (out of 281 patients). The
success as bridge to transplantation in single-ventricle patients
was lower than for biventricular patients with VAD device [11
of 26 (42.3%) vs. 185 of 255 (72.5%); P = 0.001, Ref. (35)]. In
patients after stage I palliation, the results were poor with only
one of nine patients reaching heart transplantation (35). There-
fore, using VADs as bridging device to transplantation most likely
is only of benefit for patients after stage II or stage III Norwood
palliation.
IMPACT ON COUNSELING OF PARENTS
Parents do expect from their pediatric cardiologist to comment
on long-term survival even in the prenatal counseling setting of
the unborn with HLHS. Clearly socio-cultural factors exert a great
influence on the decision of parents to ask for termination of
pregnancy after prenatal diagnosis of HLHS or to decide for med-
ical and surgical treatment after birth of their child with HLHS.
The attitudes of care provider also will influence the decision
of parents and it is interesting to note that technical capability
to provide care for the HLHS patient does not mean that care
providers would make the same decisions when confronted with
a prenatal diagnose of HLHS in their own family as shown by
a survey published by Jacobs and coworkers in 2005 (36): more
than two-thirds answered that they would recommend termina-
tion of pregnancy to their daughter (or son) whereas 73% of the
same audience would recommend Norwood palliation to their
patients.
It is therefore necessary to emphasize that the current treat-
ment options offer palliation but not cure and that problems are
to be expected on the long run. The overall reduced life expectancy
should be addressed honestly in order to avoid false expectations.
For the time being, a realistic presentation of options and pitfalls
in the care for the patient with HLHS should guide the counseling
of parents and help them to better cope with the problems of their
child with HLHS.
In summary, advances in pre-operative management, oper-
ative techniques, and postoperative care have clearly improved
mid-term prognosis for the patient with HLHS. However, a fur-
ther improvement in long-term prognosis only will be achieved
when we will be able to control pulmonary vascular develop-
ment and improve our abilities to treat RV heart failure in these
patients. These aims may be reached by promoting translational
research and by learning from other disciplines aiming to control
angiogenesis and ventricular function.
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